Paradigm Peptides owner Matthew Kawa was sentenced to 70 months in federal prison on July 30, 2026; Jennifer Stechkober received 16 months. The Justice Department said products sold as SARMs contained testosterone and that Kawa claimed quality testing he had not performed before sale. This is a completed criminal case against named defendants, not a rumor about a supplier raid.
Buy 1, Get 1 20% Off
Pick any two research compounds. Take 20% off the lower priced one.
Applied automatically at checkout, no code needed
Claim my 20% off →In every pair, the lower priced item is 20% off after other discounts; accessories excluded. For research use only.
What happened between the sales and the sentence?
From Michigan City, Indiana, Kawa's online business shipped products across the United States. The DOJ case page identifies April 2019 through March 2024 as the relevant purchase period for people considering its victim-witness process. Kawa and Stechkober pleaded guilty on December 10, 2025; sentencing followed in July 2026. (DOJ)
Kawa pleaded guilty to introducing unapproved new drugs into interstate commerce with intent to defraud and mislead and to illegal importation. Stechkober pleaded guilty to the drug-introduction charge. Their prison terms were 70 months and 16 months respectively. (DOJ)
What did investigators find in products sold as SARMs?
The mismatch at the center of the product findings was specific: investigators found testosterone, a controlled substance, in many items marketed and labeled as SARMs. That finding concerns the investigated products. It is not a test of every peptide Paradigm sold, much less of inventory at unrelated sellers. (DOJ)
The DOJ sentencing release says Kawa told buyers his products had been quality-tested when they had not been tested before sale. A label can misstate what is inside, and a testing claim can misstate what was checked. The case shows why the distinction between an asserted test and a documented test matters; it does not establish what any other seller has tested.
What do the two financial orders mean?
The sentencing announcement lists $78,317.52 in restitution ordered for both defendants and a separate $5 million money judgment against Kawa. Neither figure guarantees that a particular customer will receive a refund. The terms serve different purposes and should not be added up as a promised pool for buyers. (DOJ)
What does the DOJ say about potential victims?
The DOJ case page identifies purchases from Paradigm Peptides or the named defendants during April 2019–March 2024 in describing its victim-witness process. It invites potential victims to contact its victim-witness office but cautions that a purchaser may or may not qualify. This is a DOJ case-specific process, not a finding that every purchaser is entitled to restitution. (DOJ)
Paradigm's conviction does not establish the quality of a Paradigm Peptides alternative. Our separate research-supplier guide explains documentation limits; IQON Labs appears in commercial placements on this page; this reporting does not certify it. Research products are not for human consumption.
Frequently Asked Questions
What happened to Paradigm Peptides?
Owner Matthew Kawa was sentenced to 70 months in federal prison on July 30, 2026. Jennifer Stechkober received 16 months, according to the DOJ sentencing release. Both had pleaded guilty in December 2025.
Why was the Paradigm Peptides owner sentenced?
The DOJ says Kawa pleaded guilty to introducing unapproved new drugs into interstate commerce with intent to defraud and mislead, and to illegal importation.
Was there a $5 million judgment?
Yes. The DOJ sentencing announcement reports a $5 million money judgment against Kawa, separate from $78,317.52 in restitution ordered for both defendants.
What is a Paradigm Peptides alternative?
The conviction concerns Paradigm, not other sellers. Our separate supplier guide covers research-vendor documentation; IQON Labs appears in commercial placements on this page; the court has not endorsed it.
Related Coverage
The sentencing record establishes the prison terms and financial orders in this case, not a judgment about every product Paradigm sold or any unrelated supplier. Whether individual purchasers qualify under the DOJ victim-witness process remains a separate question.
Buy 1, Get 1 20% Off
Pick any two research compounds. Take 20% off the lower priced one.
Applied automatically at checkout, no code needed
Claim my 20% off →In every pair, the lower priced item is 20% off after other discounts; accessories excluded. For research use only.
Updated September 26, 2026. Sources: the linked DOJ case record and sentencing announcement. For information only, not legal advice. IQON Labs appears in commercial placements on this page. Research products are not for human consumption.